Japanese Journal of Clinical Oncology

Nakagawara,, Akira;Morita,, Ken;Okabe,, lkuo;Uchino,, Junichi;Ohi,, Ryoji;Iwafuchi,, Makoto;Matsuyama,, Shiro;Nagashima,, Kikuo;Takahashi,, Hideyo;Nakajo,, Toshio;Hirai,, Yoshinori;Tsuchida,, Yoshiaki;Saeki,, Morihiro;Yokoyama,, Jotaro;Nishi,, Toshiji;Okamoto,, Eizo;Suita,, Sachiyo

doi: 10.1093/oxfordjournals.jjco.a039424pmid: N/A

Abstract In 1971, the Japanese Society of Pediatric Surgeons' Committee on Malignancies proposed new criteria for neuroblastoma staging. It was fundamentally, based on the system of Evans et al. described in 1971. The main difference was the separation of stage IV disease into stages IV-A, with metastases to bone, orbita, distant lymph nodes and viscera other than liver, IV-B, the primary tumor extending over the midline and with metastases to bone marrow, liver and skin, and IV-S, which was the same as that of Evans et al. The new criteria did not include the resectability of the primary tumor, assessment of regional lymph node involvement or any other disease assessment resulting from therapeutic intervention. For the purpose of international usage, the Japanese system has been newly formulated and proposed as the Japanese Tumor Node Metastasis (TNM) Postsurgical Histopathological Classification for Neuroblastoma. In the present report, 495 neuroblastomas, registered between 1970 and 1985, were analyzed retrospectively according to the International Union Against Cancer (UICC) TNM classification and the proposed Japanese TNM system. The analyses suggested that the Japanese system reflected both the extent of tumor invasion and its biological neuroblastoma characteristics better than the UICC TNM classification based on statistical analysis. Neuroblastoma, TNM classification, Japanese staging system This content is only available as a PDF. © Oxford University Press

Shimano,, Satoshi;Fukushima,, Michio;Nishikawa,, Akira;Yamakawa,, Yasushi;Takashima,, Satoru;Satoh,, Masaaki;Minase,, Takashi;Kutuzwa,, Takeshi;Hashimoto,, Masayoshi

doi: 10.1093/oxfordjournals.jjco.a039436pmid:

Shibata,, Kunitaka;Kobayashi,, Tetsuro;Matsuura,, Nariaki;Shimano,, Takashi;Mori,, Takesada

doi: 10.1093/oxfordjournals.jjco.a039425pmid: N/A

Abstract Three monoclonal antibodies, designated FP-1, FP-2 and FP-3, were obtained by immunizing a BALB/c mouse with dispersed human fetal pancreatic cells and using hybridoma technology. FP-1, FP-2 and FP-3 reacted specifically, respectively, with the ductal epithelial, acinar and islet cells, of the fetal pancreas as well as with adult human pancreatic tissue, suggesting a use in the discrimination of pancreatic cell types. Upon screening various tumor tissues, FP-1 was found to react with adenocarcinomas of the pancreas (16/23), stomach (7/8), colon (4/6) and gall bladder (2/2) as well as with the three malignant cell lines, PANC-1 (pancreas), HT-29 (colon) and LoVo (colon). In contrast to FP-1, FP-2 and FP-3 reacted with only 5% (2/39) and 0% (0/39), respectively, of these adenocarcinomas. Although FP-3 did not react with any of these adenocarcinomas, it did react with various APUDoma cells such as islet cell tumors of the pancreas (3/5), pheochromocytomas (2/2), medullary thyroid carcinomas (2/3) and gastrointestinal carcinoids (1/3). FP-3 thus appears to be the first monoclonal antibody with extremely high endocrine cell specificity. Monoclonal antibody, Fetal pancreas, Pancreatic cancer, APUDoma cell, Endocrine cell This content is only available as a PDF. © Oxford University Press

Nagata,, Kazuhiko;Tanaka,, Yoshiya;Oda,, Susumu;Yamashita,, Uki;Eto,, Sumiya

doi: 10.1093/oxfordjournals.jjco.a039426pmid: N/A

Abstract The role of interleukin 1 (IL 1) in the growth of human multiple myeloma cells was studied in vitro. In the culture supernatant of myeloma cells, IL 1-like activities were detected by the stimulating on murine thymocyte proliferative response and these adivities were completely inhibited by anti-IL 1β antibody but not by anti-IL 1α antaibody. Recombinant human IL 1α (alpha) and IL 1β (beta) enhanced the proliferation of myeloma cells freshly isolated from the bone marrow of patients with multiple myeloma. Moreover, the spontaneous growth of myeloma cells was partly inhibited by anti-IL 1β antibody but not by anti-IL 1α antibody. IL 1 receptor was detected on the surface of 50% of the myeloma cells by flow cytofluorometric analysis. The expression of IL 1 receptor (IL 1R) on myeloma cells was also analyzed using a binding assay with 125 I-labeled IL 1α. By Scatchard plot analysis, two classes of IL 1R were found on the myeloma cells. The major class (2700-7200 sites/cell) had the lower affinity (Kd=0.88 − 1.2×10−9M) and the minor class (70-500 sites/cell) had the higher affinity (Kd=3.1 − 38.0×10−12M) Furthermore, a tendency for a proliferation of IL 1R-positive myeloma cells to be induced by adding exogenous IL 1 was observed. These results suggest IL 1β to be one of the autocrine growth factors for multiple myeloma cells. Multiple myeloma, Interleukin 1, Autocrine growth system, Interleukin 1 receptor, Human This content is only available as a PDF. © Oxford University Press

Sawada,, Masumi;Yamasaki,, Masato;Urabe,, Takeshi;Hashimoto,, Kazumasa;Katayama,, Shoichi

doi: 10.1093/oxfordjournals.jjco.a039427pmid: N/A

Abstract Clinical and pathological details of 10 patients with stage I low malignant potential tumors of the ovary, between September, 1969, and February, 1988, have been reviewed. The mean age of the patients was 46.6 years. Six patients had serous and four had mucinous tumors. Of the 10 patients, five had a unilateral salpingo-oophorectomy, one had a bilateral salpingo-oophorectomy and four a total abdominal hysterectomy and bilateral salpingo-oophorectomy. The mean duration of follow-up was 12.8 years. All patients have remained alive and disease-free. A recurrence occurred in one patient who has been managed well by additional surgery. Stage I ovarian tumor of low malignant potential appears to carry a favorable prognosis. Ovarian tumor of low malignant potential, Recurrence, Long-trem survival This content is only available as a PDF. © Oxford University Press

Lino,, Yuichi;Yoshida,, Masao;Tago,, Toshihiko;Owada,, Susumu;Sugamata,, Noritaka;Horiuchi,, Ryuya

doi: 10.1093/oxfordjournals.jjco.a039428pmid: N/A

Abstract Effects of sequential and combined immuno-endocrine therapies using OK-432 (Picibanil) and tamoxifen (LAM) on the growth of 7,12-dimethylbenz [α] anthracene (DMBA)-induced carcinoma were examined in 128 female Sprague-Dawley (SD) rats. The rats were divided into six groups: control (no treatment), tamoxifen, OK-432, simultaneous immuno-endocrine OK-432 and TAM (OK-432+TAM) therapy, two types of sequential immuno-endocrine therapy of the OK-432 and TAM groups [OK-432 (1 wk)→TAM (4 wk) and OK-432 (2 wk)→TAM (3 wk)]. Each group was treated consecutively for five weeks. The response rates in the TAM alone group, the [OK-432 (1 wk)→TAM (4 wk)] group and the [OK-432+TAM (5 wk)] group were significantly higher than in the control group. When the results among the treated groups were compared, the response rate in the [OK-432 (1 wk)→TAM (4 wk)] group was significantly higher than in the OK-432 alone or TAM alone groups. The response rate in the [OK-432 (2 wk)→TAM (3 wk)] group, however, was lower than in the TAM alone group. The response rate in the OK-432+TAM group was, moreover, not significantly superior to that in the TAM alone group. These results suggest OK-432 not to potentiate the antitumor effect of TAM since the response rate of the combined OK-432/TAM therapy was not always significantly superior to that of the TAM treatment. Immuno-endocrine therapy, Rat mammary carcinoma, OK-432, Tamoxifen This content is only available as a PDF. © Oxford University Press

Yamada,, Kouzou;Saijo,, Nagahiro;Kojima,, Akira;Ohe,, Yuichiro;Tamura,, Tomohide;Sasaki,, Yasutsuna;Eguchi,, kenji;Shinkai,, Tetsu;Goya,, Tomoyuki;Kondou,, Haruhiko;Tsuchiya,, Ryosuke;Naruke,, Tsuguo;Suemasu,, Keiichi;Ono,, Ryosuke;Matsuno,, Yoshihiro;

Kotake,, Toshihiko;Kinouchi,, Toshiaki;Saiki,, Shigeru;Kuroda,, Masao;Miki,, Tsuneharu;Kiyohara,, Hisakazu;Usami,, Michiyuki

doi: 10.1093/oxfordjournals.jjco.a039430pmid: N/A

Abstract Human lymphoblastoid interferon-alpha was administered intramuscularly at a dose of 5×106 units/day to 20 metastatic renal cell carcinoma patients. For potentiating the antitumor effect of interferon, cimetidine was also given to them orally at a dose of 800 mg/day. The combination therapy obtained a complete response in three patients (15%) and a partial response in three (15%). Nine patients (45%) had stable disease and five (25%), progressive disease. All six patients who responded to the combination therapy had been nephrectomized and had pulmonary metastases. Two of them also had metastases to other sites (mediastinal lymph nodes and bone). The pulmonary metastases were significantly more receptive to interferon therapy than those at the other sites. The average times before a response was obtained were 2.2 months for a minor response, 2.7 months for a partial response and 3.0 months for a complete response, and the average duration of response was 26 months. The six patients who responded survived for a significantly longer period than the 14 non-responding patients treated with interferon in combination with cimetidine. The major toxicities encountered were fever, fatigue and anorexia due to interferon, and the combination therapy was well tolerated except in three patients. The results suggest that interferon-alpha and cimetidine combination therapy may be of use in the management of patients with metastatic renall cell carcinoma. Renal cell carcinoma, Intereron alpha, Cimetidine, Combination immunotherapy This content is only available as a PDF. © Oxford University Press

Tanabe,, Noboru;Goto,, Tatsuhiko;Inagaki,, Jiro;Kimura,, Kiyoji

doi: 10.1093/oxfordjournals.jjco.a039431pmid: N/A

Abstract Episodes of septicemia (114) in patients with solid cancers at Nagoya Memorial Hospital were analyzed from April 1985 to June 1986. The underlying malignancies were predominantly gastric and colon cancers. Almost all the cancers were in advanced stages, the most frequent patient performance status being 4. Hypogammaglobulinemia and granulocytopenia were not, however frequent among these patients. The major microbes detected from blood cultures were Candida sp., Staphylococcus aureus and Staphylococcus epidermidis. Preceding chemotherapies were mainly combination chemotherapies containing Cisplatin (CDDP). The major pathogen, Candida sp., was detected frequently from Hickman's catheter. Thirty-one percent of patients died within 14 days of the septicemia diagnosis (two were cases of septic shock). Cancer, Sepsis, Fungal infection, Candidemia, Central venous catheter This content is only available as a PDF. © Oxford University Press

Akiyama,, Yuichi;Kubota,, Masaru;Mikawa,, Haruki;Nakashima,, Yasuaki;Yamabe,, Hirohiko

doi: 10.1093/oxfordjournals.jjco.a039432pmid: N/A

Abstract A case of embryonal carcinoma of the testis after acute myelomonocytic leukemia is reported. The interval between the initial diagnosis of leukemia and the appearance of embryonal carcinoma was almost three years. Although the patient had received neither irradiation nor alkylating agents, the case is regarded as one of secondary malignancy. Possible contributing factors are discussed. Embryonal carcinoma, Acute myelomonocytic leukemia, secondary neoplasm This content is only available as a PDF. © Oxford University Press